Leukemia: all 5,475 studies

Page 24 of 55. Open to participants first (629), then studies with results posted, then the rest; newest registration first within each.

• Study of Oral Venetoclax Tablets to Evaluate Adverse Events and Change in Disease Activity in Participants of Any Age With Acute Myeloid LeukemiaCompletedNCT04813263
• A Phase 1 Study of SH1573 Capsules in Subjects With Refractory or Relapsed Acute Myelogenous LeukemiaStatus unknownNCT04806659Phase 1
• Window Trial to Evaluate Molecular Response to PI3K Inhibition With Copanlisib in r/r Adult B-cell ALLTerminatedNCT04803123Early Phase 1
• Universal Chimeric Antigen Receptor-modified AT19 Cells for CD19+ Relapsed/Refractory Hematological MalignanciesStatus unknownNCT04796688Phase 1
• Study of Efficacy and Safety of CML-CP Patients Treated With Asciminib Versus Best Available Therapy, Previously Treated With 2 or More Tyrosine Kinase InhibitorsCompletedNCT04795427Phase 2
• Sequential CD19 and CD22 CAR-T Therapy for Newly Diagnosed Ph+ B-ALLCompletedNCT04788472Phase 2
• Influence of Co-existing Mutations on Sorafenib Maintenance Therapy After Allo-HSCT for Patients With FLT3-ITD AMLCompletedNCT04788420
• CD7 CAR-T in the Treatment of CD7 Positive Refractory Relapsed Acute LeukemiaStatus unknownNCT04785833Not applicable
• Ipilimumab, Ibrutinib, and Nivolumab for the Treatment of Chronic Lymphocytic Leukemia and Richter TransformationWithdrawnNCT04781855Phase 1
• Study of the Infusion of ARI-0001 Cells in Patients With CD19 + Acute Lymphoid Leukemia Resistant or Refractory to TherapyActive, not recruitingNCT04778579Phase 2
• Classical Monocyte Kinetics in Chronic Myelomonocytic LeukemiaCompletedNCT04775121Not applicable
• Effect of Digital Health Coaching Program on Self-efficacy and Patient Reported Outcomes of Patients With Newly Diagnosed Acute Myeloid Leukemia or Chronic Lymphocytic LeukemiaCompletedNCT04774744Not applicable
• Pharmacogenomic Analysis in Pediatric Acute Lymphoblastic LeukemiaCompletedNCT04770922
• Trial in AML Secondary to MPNs Patients, Unfit for Intensive Chemotherapy, Investigating a Treatment Combination Including Decitabine and VenetoclaxActive, not recruitingNCT04763928Phase 2
• Humanized CD7 CAR T-cell Therapy for r/r CD7+ Acute LeukemiaStatus unknownNCT04762485Phase 1/2
• A Study of Evorpacept (ALX148) With Venetoclax and Azacitidine for Acute Myeloid Leukemia (ASPEN-05)TerminatedNCT04755244Phase 1
• Clinical Study With Ibrutinib and Venetoclax for Patients With Relapsed/Refractory Chronic Lymphocytic LeukemiaActive, not recruitingNCT04754035Phase 2
• Individualized Induction Therapy for Non-elderly Acute Myeloid Leukemia Patients With Adverse Risk FeaturesStatus unknownNCT04752527Phase 2
• A Safety, Tolerability and Preliminary Efficacy Study of CC-90011 in Combination With Venetoclax and Azacitidine in R/R Acute Myeloid Leukemia and Treatment-naïve Participants Not Eligible for Intensive TherapyTerminatedNCT04748848Phase 1
• Induced-T Cell Like NK Cells for B Cell MalignanciesStatus unknownNCT04747093Phase 1/2
• Investigator-initiated Clinical Trial (Phase II) of Cancer Vaccine "Dainippon Sumitomo Phama(DSP)-7888" for Acute Myeloid Leukemia Patients.Status unknownNCT04747002Phase 2
• Clinical Characteristics of Patients With Leukemia and COVID-19CompletedNCT04745416
• A Phase I, Open-Label, Dose Escalation and Cohort Expansion Study of BS HH 002.SA in Patients With AML and MDSStatus unknownNCT04743115Phase 1
• Sequential CD19 and CD22 CAR-T Therapy for Newly Diagnosed Ph- B-ALLStatus unknownNCT04740203Phase 1/2
• A Study of CFI-400945 With or Without Azacitidine in Patients With AML, MDS or CMMLActive, not recruitingNCT04730258Phase 1/2
• Dual Target CAR-T Cells in B-cell Acute Lymphoblastic LeukemiaStatus unknownNCT04723901Phase 1/2
• PD-1 Inhibitor Combined With Azacytidine and Homoharringtonine，Cytarabine, G-CSF for Refractory or Relapsed AMLStatus unknownNCT04722952Phase 3
• Sequential Treatment With Ponatinib and Blinatumomab vs Chemotherapy and Imatinib in Newly Diagnosed Adult Ph+ ALLActive, not recruitingNCT04722848Phase 3
• Targeting CD19 and CD22 CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory Acute B Lymphocytic LeukemiaStatus unknownNCT04714593Phase 1/2
• Safety and Early Efficacy Study of TBX-2400 in Patients With AML or MyelofibrosisStatus unknownNCT04709458Phase 1
• Prognostic Value of CD318 in AML at Assiut University Hospital.Status unknownNCT04708444
• Efficacy of Intermediate and High Intensity Regimens in Patients With Relapsed Acute Lymphoblastic LeukemiaCompletedNCT04699162
• A Mobile Intervention (txt4TKI) for the Improvement of Tyrosine Kinase Inhibitor Management in Patients With Chronic Myeloid LeukemiaCompletedNCT04694820Not applicable
• A Time-Limited Approach to Treatment With Ibrutinib for Chronic Lymphocytic Leukemia and Small Lymphocytic LymphomaWithdrawnNCT04694560
• TAA6 Cell Injection In The Treatment of Patients With Relapsed / Refractory Acute Myeloid LeukemiaStatus unknownNCT04692948Not applicable
• Anakinra in Previously Untreated Chronic Lymphocytic Leukemia PatientsStatus unknownNCT04691765Phase 1
• Umbilical Cord Blood Transfusion in Consolidation Therapy of Elderly Patients With Acute Myeloid LeukemiaStatus unknownNCT04687657Phase 1
• Risk-adapted Therapy for Primary Acute Myeloid LeukemiaCompletedNCT04687098Phase 2
• the Efficacy and Safety of CLAE in R/R T-ALL/LBLStatus unknownNCT04679506
• Flotetuzumab Expanded Access ProgramNo longer availableNCT04678466
• CD123 Redirected T Cells for AML in Pediatric SubjectsTerminatedNCT04678336Phase 1
• Evaluation of Long-term Health Status and Quality of Life in Adult Survivors With Philadelphia-negative Acute Lymphoblastic Leukemia/Lymphoma Treated With an Intensive Pediatric or Pediatric-inspired ProtocolStatus unknownNCT04677231
• Sorafenib Maintenance for Prophylaxis of Leukemia Relapse in Allo-HSCT Recipients With FLT3 Negative Acute LeukemiaStatus unknownNCT04674345Phase 2/3
• TL-895 and KRT-232 Study in Acute Myeloid LeukemiaActive, not recruitingNCT04669067Phase 1/2
• SARS-CoV-2 Donor-Recipient Immunity TransferCompletedNCT04666025
• Ibrutinib for the Treatment of Patients With B-Cell Malignancies Who Are Infected With Coronavirus Disease 2019 (COVID-19)WithdrawnNCT04665115Phase 2
• Effectiveness of Exercise Through Video Games in Reducing Fatigue Among Children With LeukemiaCompletedNCT04663516Not applicable
• Glasdegib-Based Treatment Combinations for the Treatment of Patients With Relapsed Acute Myeloid Leukemia Who Have Undergone Hematopoietic Cell TransplantationWithdrawnNCT04655391Phase 1
• Study of Oral Venetoclax Tablets in Combination With Intravenous Obinutuzumab Injection to Assess Achievement of Best Response in Adult Participants With Chronic Lymphocytic LeukemiaTerminatedNCT04655261
• CD19 Targeted CAR T Cell Therapy in Patients With Relapsed/ Refractory B Cell Acute Lymphoblastic Leukaemia (ALL)Status unknownNCT04653493Phase 1
• CD19 and CD22 Targeted CAR-T Cell Therapy for Relapsed/Refractory B Cell Leukemia and LymphomaStatus unknownNCT04649983Phase 1/2
• Safety and Efficacy of CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell Leukemia and LymphomaStatus unknownNCT04648475Phase 1/2
• Innate T Cells and TKI DiscontinuationActive, not recruitingNCT04645706
• Chemotherapy-related Cognitive Impairment and Acute LeukemiaCompletedNCT04644419
• Impact of Treatment With Targeted Therapies on the Generation of CAR T Cells in CLL PatientsStatus unknownNCT04640909Not applicable
• A Study of TAS1553 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML) and Other Myeloid NeoplasmsTerminatedNCT04637009Phase 1
• A Trial to Evaluate the Safety and Efficacy of oNKord® in Subjects With Acute Myeloid LeukemiaStatus unknownNCT04632316Phase 1/2
• FT819 in Subjects With B-cell MalignanciesActive, not recruitingNCT04629729Phase 1
• Effects of Prebiotics on Gut Microbiome in Patients Undergoing HSCTCompletedNCT04629430Not applicable
• IFN-γ to Treat Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) That Has Relapsed After Allogeneic Hematopoietic Stem Cell TransplantationCompletedNCT04628338Early Phase 1
• Intermittent Fasting and CLL/SLLCompletedNCT04626843Phase 1
• CAR-T for Children With Relapsed and Refractory Acute Lymphoblastic LeukemiaStatus unknownNCT04626765Early Phase 1
• Adult B-ALL Treated by CART Cell Bridging Allogeneic Hematopoietic Stem Cell TransplantationStatus unknownNCT04626726Early Phase 1
• Aerobic Versus Resistive Training on Functional Capacity in Acute Myeloid LeukemiaCompletedNCT04617145Not applicable
• FT538 in Subjects With Advanced Hematologic MalignanciesTerminatedNCT04614636Phase 1
• CD19-CAR-T2 Cells for CD19 Positive B Cell MalignanciesCompletedNCT04605666Phase 2
• A Distress Reduction Intervention for Patients With BCR-ABL-Negative MPNs or CML on Tyrosine Kinase InhibitorsCompletedNCT04605211Not applicable
• GNR-084 Safety and Pharmacological Characteristics in Refractory or Relapse B-cell Precursor ALLTerminatedNCT04601584Phase 1/2
• Bright White Light Therapy for the Improvement of Sleep, Fatigue, Distress, Depression, and Anxiety in Hospitalized Leukemia PatientsCompletedNCT04597086Not applicable
• Measurement of Oncostatin M, Leukemia Inhibitory Factor and Interleukin-11 Levels of Patients With Periodontal DiseaseCompletedNCT04597073Not applicable
• Effects of a Digital Patient Platform (CMyLife) for Patients With Chronic Myeloid Leukemia (CML) on Information Provision, Patient Empowerment, Medication Compliance, Guideline Adherence and Quality of LifeCompletedNCT04595955Not applicable
• Pharmacists Coordinated Care Oncology Model (PCOM) for Patients Taking Oral Anti-cancer MedicationsTerminatedNCT04595851Not applicable
• Interactive Survivorship Program for the Improvement of Healthcare Resources in Adolescent and Young Adult Cancer Survivors, INSPIRE-AYA StudyCompletedNCT04593277Not applicable
• A Dose Escalation and Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7283420.CompletedNCT04580121Phase 1
• A Study of REduction And DIscontinuation Treatment of TKI (Imatinib, Nilotinib, Dasatinib and Bosutinib)Status unknownNCT04578847Phase 2
• CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell LymphomaCompletedNCT04578600Phase 1
• Cell Therapy for CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using CD7-Specific CAR-T CellsCompletedNCT04572308Phase 1
• Results From a Mexican Acute Promyelocytic Leukemia.CompletedNCT04562818
• MAP to Provide Access to Nilotinib, for Patients With Relapsed or Refractory Philadelphia Chromosome Positive Acute Lymphoblastic LeukemiaNo longer availableNCT04559555
• TT52CAR19 Therapy for B-cell Acute Lymphoblastic Leukaemia (B-ALL)CompletedNCT04557436Phase 1
• Blinatumomab Followed by High-dose Chemotherapy for Ph-negative Acute Lymphoblastic Leukemia (ALL)CompletedNCT04554485Phase 2
• Ponatinib Plus Reduced-intensity Chemotherapy in the First-line Treatment of Adult Patients With Ph+ ALLTerminatedNCT04554459Phase 2
• Assesment of JL1 Expression in Acute LeukemiaStatus unknownNCT04554381Phase 1
• Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed CancersTerminatedNCT04553692Phase 1
• Physical Activity to Improve Patient Reported Outcomes for Adults With Acute LeukemiaCompletedNCT04552912Not applicable
• A Study Comparing Haploidentical Hematopoietic Stem Cell Transplantations (HSCTs) From Young Non-first-degree and Older First-degree Donors in Hematological MalignanciesActive, not recruitingNCT04547049Phase 3
• Safety and Efficacy Study of SL1904B CAR-T Cells for Relapsed or Refractory B-Cell Acute Lymphocyte LeukemiaStatus unknownNCT04546893Not applicable
• Combined Inhibition of PD-1 and DNA Hypomethylating Agent +/- Chemotherapy in High-risk AML or Elderly Patients With AML Who Are Unfit for Intensive ChemotherapyStatus unknownNCT04541277Phase 2
• Identification and Evaluation of Patients at Risk of Developing Cardiotoxicity After Receiving Chemotherapy for Breast Cancer, Lymphoma or LeukemiaActive, not recruitingNCT04541212
• Fludarabine, Cytarabine, and Pegcrisantaspase for the Treament of Relapsed or Refractory LeukemiaTerminatedNCT04526795Phase 1
• IDH2-Post-Allo-Trial for Patients with IDH2-mut Myeloid Neoplasms After Allo-SCTCompletedNCT04522895Phase 2
• Nilotinib, for Patients With CML-CP or CML-APNo longer availableNCT04518644
• TP-0903 for the Treatment of FLT3 Mutated Acute Myeloid LeukemiaCompletedNCT04518345Early Phase 1
• A Study of Oral Venetoclax Tablet in Combination With Subcutaneous Low-Dose Cytarabine (LDAC) Injection to Assess Adverse Events in Adult Japanese Participants With Acute Myeloid Leukemia (AML)CompletedNCT04509622Phase 3
• CD19/CD22-Dual-STAR-T for Patients With B Cell Acute Leukemia(B-ALL)TerminatedNCT04508842Phase 1
• Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLLStatus unknownNCT04502394Phase 1/2
• Phase 1 First in Human Study of ZN-d5 as a Single AgentCompletedNCT04500587Phase 1
• Alvocidib in Combination With Decitabine and Venetoclax in Patients With Relapsed or Refractory AML or as Frontline Therapy in Unfit Patients With AMLWithdrawnNCT04493099Phase 1/2
• Study of Azacytidine Combined With Lenalidomide As Maintenance Therapy Based on MRD Monitoring in AMLStatus unknownNCT04490707Phase 3
• Vitamin D and Methotrexate Adverse EffectsStatus unknownNCT04488237

← Leukemia overview